安罗替尼联合紫杉醇和顺铂治疗晚期食管癌的临床疗效及其安全性

Clinical efficacy and safety of anlotinib combined with paclitaxel and cisplatin in the treatment of advanced esophageal cancer

目的观察安罗替尼联合紫杉醇和顺铂治疗晚期食管癌的临床疗效及其安全性。方法回顾性选取2020年1—7月九江市第一人民医院八里湖总院收治的晚期食管癌患者80例,依据治疗方法分为常规化疗组(n=40)与安罗替尼组(n=40)。常规化疗组予以紫杉醇联合顺铂治疗,安罗替尼组在常规化疗组基础上予以盐酸安罗替尼胶囊。2组均治疗6个周期。随访1年,比较2组治疗后3、6、9个月病灶局部控制率,中位生存期、肿瘤无进展时间,治疗前及治疗6个周期后前清蛋白(PA)、清蛋白(Alb)、血红蛋白(Hb)、淋巴细胞计数(TLC),不良反应发生情况。结果安罗替尼组总缓解率为85.00%,高于常规化疗组的45.00%(χ^(2)=14.066,P<0.001)。治疗后3、6、9个月,安罗替尼组病灶局部控制率高于常规化疗组(P<0.05)。安罗替尼组中位生存期、肿瘤无进展时间长于常规化疗组(P<0.01)。治疗6个周期后,2组PA、Alb、Hb、TLC水平高于治疗前,且安罗替尼组高于常规化疗组(P<0.01)。安罗替尼组不良反应总发生率为27.50%,与常规化疗组的25.00%比较,差异无统计学意义(χ^(2)=0.065,P=0.799)。结论安罗替尼联合紫杉醇和顺铂治疗晚期食管癌的临床疗效确切,可有效提高病灶局部控制率,改善患者营养状况,延长生存期,且安全性较高。

Objective To observe clinical efficacy and safety of anlotinib combined with paclitaxel and cisplatin in the treatment of advanced esophageal cancer.Methods A total of 80 cases of patients with advanced esophageal cancer were retrospectively selected from January to July 2020 in Jiujiang First People’s Hospital Balihu General Hospital,which were randomly divided into conventional chemotherapy group(n=40)and anlotinib group(n=40)according to the treatment methods.The conventional chemotherapy group was treated with paclitaxel combined with cisplatin,the anlotinib group was given anlotinib hydrochloride capsule on the basis of conventional chemotherapy group.Both groups were treated for 6 cycles.Follow-up for 1 year,the local control rate of lesions of 3,6 and 9 months after treatment,median survival time,tumor progression free time,PA,Alb,Hb,TLC before treatment and after 6 cycles of treatment,incidence of adverse reactions were compared between the two groups.Results The total remission rate in the anlotinib group was 85.00%,which was higher than 45.00%in the conventional chemotherapy group(χ^(2)=14.066,P<0.001).At 3,6 and 9 months after treatment,the local control rate of lesions in the anlotinib group was higher than that in the conventional chemotherapy group(P<0.05).The median survival time and tumor progression free time in the anlotinib group were longer than those in the conventional chemotherapy group(P<0.01).After 6 cycles of treatment,the levels of PA,Alb,Hb and TLC in the two groups were higher than those before treatment,and those in the anlotinib group were higher than those in the conventional chemotherapy group(P<0.01).The total incidence of adverse reactions in the anlotinib group was 27.50%,which was not statistically significant compared with 25.00%in the conventional chemotherapy group(χ^(2)=0.065,P=0.799).Conclusion Anlotinib combined with paclitaxel and cisplatin have an exact clinical effect for advanced esophageal cancer,which can effectively improve the local control rate of lesions,improve the nutritional status,and extend survival time patients,and with high safety.